UI 059
Alternative Names: UI-059Latest Information Update: 17 May 2024
At a glance
- Originator Korea United Pharm Inc
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Gastro-oesophageal reflux
Most Recent Events
- 07 May 2024 Korea United Pharm Inc plans a phase I pharmacokinetic and safety trial in healthy adult volunteers in South Korea in July 2024 (PO) (NCT06393881)
- 08 Oct 2023 Phase-I clinical trials in Gastro-oesophageal reflux (In volunteers) in South Korea (PO) (NCT06141577)